Article Information
History
- July 6, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Astha Thakkar1,
- Kith Pradhan2,
- Benjamin Duva1,
- Juan Manuel Carreño3,5,
- Srabani Sahu1,
- Victor Thiruthuvanathan1,
- Sean Campbell6,
- Sonia Gallego1,
- Tushar D Bhagat1,
- Johanna Rivera7,
- Gaurav Choudhary1,
- Raul Olea1,
- Maite Sabalza8,
- Lauren C. Shapiro1,
- Matthew Lee1,
- Ryann Quinn1,
- Ioannis Mantzaris1,
- Edward Chu1,
- Britta Will1,
- Liise-anne Pirofski7,
- Florian Krammer3,4,5,
- Amit Verma1,* and
- Balazs Halmos1,*
- 1Department of Oncology, Montefiore Einstein Cancer Center, Albert Einstein College of Medicine
- 2Department of Epidemiology and Population Health, Albert Einstein College of Medicine
- 3Department of Microbiology, Icahn School of Medicine at Mount Sinai
- 4Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai
- 5Center for Vaccine Research and Pandemic Preparedness (C-VARPP), Icahn School of Medicine at Mount Sinai
- 6Department of Pathology, Montefiore Medical Center
- 7Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center
- 8EUROIMMUN, US
- ↵*Correspondence to: Dr. Balazs Halmos, bahalmos{at}montefiore.org or Dr. Amit Verma, amit.verma{at}einsteinmed.edu
Posted July 06, 2022.
Efficacy and longevity of immune response to 3rd COVID-19 vaccine and effectiveness of a 4th dose in severely immunocompromised patients with cancer
